Familial thrombomodulin anomalies

Familial thrombomodulin anomalies (also known as thrombomodulin-related thrombophilia or familial thrombophilia due to thrombomodulin defect) are rare inherited disorders of the coagulation system caused by mutations in the THBD gene, which encodes thrombomodulin. Thrombomodulin is a glycoprotein expressed on the surface of endothelial cells that plays a critical role in the regulation of blood coagulation. It acts as a cofactor for thrombin-mediated activation of protein C, a natural anticoagulant. When thrombomodulin function is impaired due to genetic variants, the protein C anticoagulant pathway is disrupted, leading to a hypercoagulable state and an increased risk of thromboembolic events. The primary clinical manifestation is an increased susceptibility to venous thromboembolism, including deep vein thrombosis and pulmonary embolism. Some affected individuals may also experience arterial thrombotic events. The severity and age of onset of thrombotic episodes can vary considerably among affected family members, and some carriers of pathogenic variants may remain asymptomatic throughout life, suggesting that additional genetic and environmental factors influence disease expression. The condition primarily affects the vascular and hematologic systems. Management of familial thrombomodulin anomalies follows general principles for inherited thrombophilias. Treatment typically involves anticoagulation therapy (such as heparin, warfarin, or direct oral anticoagulants) during acute thrombotic episodes and may include long-term prophylactic anticoagulation in individuals with recurrent events or additional risk factors. Genetic counseling is recommended for affected families. There is currently no specific targeted therapy to correct the underlying thrombomodulin deficiency.

Common questions about Familial thrombomodulin anomalies